4.8 Article

Bioactive Iridium Nanoclusters with Glutathione Depletion Ability for Enhanced Sonodynamic-Triggered Ferroptosis-Like Cancer Cell Death

Journal

ADVANCED MATERIALS
Volume 34, Issue 45, Pages -

Publisher

WILEY-V C H VERLAG GMBH
DOI: 10.1002/adma.202206286

Keywords

ferroptosis; GSH depletion; iridium oxide; nanoclusters; sonodynamic therapy

Funding

  1. NSFC Key Projects of International Cooperation and Exchanges [81720108023]
  2. National Natural Science Foundation of China [82001943, 82172074]
  3. Shanghai Key Discipline of Clinical Imaging Fund [shslczdzk03203]
  4. Excellent Youth Cultivation Program of Shanghai Sixth People's Hospital [ynyq202203]

Ask authors/readers for more resources

This study developed a ferroptosis-inducing agent that can trigger ferroptosis-like cancer cell death through sonodynamic therapy. The agent promotes the accumulation of lipid peroxide through ultrasound stimulation and enhances ferroptosis by depleting glutathione. Experimental results demonstrate that the agent has significant ability to reduce intracellular glutathione content and enhance sonodynamic therapy-triggered ferroptosis-like cancer cell death.
Ferroptosis is a regulated form of necrotic cell death that involves the accumulation of lipid peroxide (LPO) species in an iron- and reactive oxygen species (ROS)-dependent manner. Previous investigations have reported that ferroptosis-based cancer therapy can overcome the limitations of traditional therapeutics targeting the apoptosis pathway. However, it is still challenging to enhance the antitumor efficacy of ferroptosis due to intrinsic cellular regulation. In this study, a ferroptosis-inducing agent, i.e., chlorin e6 (Ce6)-conjugated human serum albumin-iridium oxide (HSA-Ce6-IrO2, HCIr) nanoclusters, is developed to achieve sonodynamic therapy (SDT)-triggered ferroptosis-like cancer cell death. The sonosensitizing role of both Ce6 and IrO2 within the HCIr nanoclusters exhibits highly efficient O-1(2) generation capacity upon ultrasound stimulation, which promotes the accumulation of LPO and subsequently induces ferroptosis. Meanwhile, the HCIr can deplete glutathione (GSH) by accelerating Ir (IV)-Ir (III) transition, which further suppresses the activity of glutathione peroxidase 4 (GPX4) to enhance the ferroptosis efficacy. Through in vitro and in vivo experiments, it is demonstrated that HCIr possesses tremendous capacity to reduce the intracellular GSH content, which enhances SDT-triggered ferroptosis-like cancer cell death. Thus, an iridium-nanoclusters-based ferroptosis-inducing agent is developed, providing a promising strategy for inducing ferroptosis-like cancer cell death.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available